Aquestive Therapeutics (NASDAQ:AQST) Stock Price Down 7% - What's Next?

Key Points

• Aquestive Therapeutics shares saw a decline of 7% during trading on Monday, falling to $5.28 per share, with trading volume also down by 19% from the average.
• Analysts express a generally positive outlook on the stock, with a consensus price target of $10.29, indicating potential upside from its current price.
• Insider selling occurred recently, with COO Cassie Jung and another insider reducing their positions, raising potential concerns among investors about their confidence in the company.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report)'s stock price dropped 7% during mid-day trading on Monday . The stock traded as low as $5.27 and last traded at $5.28. Approximately 1,372,299 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 1,694,918 shares. The stock had previously closed at $5.67.

Wall Street Analysts Forecast Growth

AQST has been the topic of several research reports. Lifesci Capital raised Aquestive Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer upped their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an "outperform" rating in a research report on Monday, September 8th. Finally, Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $10.29.

Aquestive Therapeutics Trading Up 6.0%

The company has a market capitalization of $546.37 million, a P/E ratio of -7.79 and a beta of 1.82. The stock has a 50 day moving average price of $4.26 and a 200 day moving average price of $3.42.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Insiders Place Their Bets

In other news, COO Cassie Jung sold 62,180 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $5.00, for a total value of $310,900.00. Following the completion of the transaction, the chief operating officer directly owned 283,346 shares in the company, valued at approximately $1,416,730. This represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter E. Boyd sold 15,000 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $5.30, for a total value of $79,500.00. Following the completion of the transaction, the insider owned 288,323 shares of the company's stock, valued at $1,528,111.90. The trade was a 4.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 77,580 shares of company stock valued at $392,800 over the last quarter. 7.85% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Summit Wealth & Retirement Planning Inc. acquired a new stake in Aquestive Therapeutics during the 1st quarter worth about $29,000. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics during the 1st quarter worth about $31,000. BNP Paribas Financial Markets grew its holdings in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock worth $31,000 after acquiring an additional 4,134 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new stake in Aquestive Therapeutics during the 1st quarter worth about $33,000. Finally, USAdvisors Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at about $33,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.